IMMUNOTECH-B

6978
0.3209.86% ( -0.035 )
Delay Closed: Nov 16, 16:08:11

Profile

About

IMMUNOTECH-B
IMMUNOTECH-B
06978.HK

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia that is in Phase II/III clinical trial; 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma that is in Phase I clinical trial; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies.

Profile

Company Name
Immunotech Biopharm Ltd
Market
SEHK
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management